Saturday, July 11, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Oncology R&D Pipeline

Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Programs 5,539

Quick answer

Oncology: NovaPharmaNews indexes 5,539 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Top sponsors

Pipeline programs

Page 51 of 116

  1. Ganoderma lucidum spore

    The First People's Hospital of Lianyungang

    Carcinoma, Non-Small-Cell Lung

    phase 2 small molecule active

    1 trial

  2. Gefitinib

    AstraZeneca

    Head and Neck Cancer

    phase 2 small molecule completed

    1 trial

  3. Gemcitabine

    Chongqing Precision Biotech Co., Ltd

    Pancreatic Cancer, Adult

    phase 2 small molecule terminated

    1 trial

  4. Gemcitabine

    HALOZYME THERAPEUTICS, INC.

    Stage IV Pancreatic Cancer

    phase 2 small molecule completed

    1 trial

  5. Gemcitabine

    Compass Therapeutics

    Metastatic Biliary Tract Cancer

    phase 2 small molecule active

    1 trial

  6. Gemcitabine

    ACTUATE THERAPEUTICS, INC.

    Soft Tissue Sarcoma

    phase 2 small molecule terminated

    1 trial

  7. Gemcitabine

    LEXICON PHARMACEUTICALS, INC.

    Locally Advanced Unresectable Pancreatic Adenocarcinoma

    phase 2 small molecule completed

    1 trial

  8. Gemcitabine

    Arcus Biosciences

    Biliary Tract Carcinoma

    phase 2 small molecule active

    1 trial

  9. Gemcitabine

    Regeneron UK Limited

    Bladder Cancer

    phase 2 small molecule active

    1 trial

  10. Gemcitabine

    ACTUATE THERAPEUTICS, INC.

    Sarcoma

    phase 2 small molecule terminated

    1 trial

  11. Gemcitabine

    Acrivon Therapeutics

    Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  12. Gemcitabine , Docetaxel

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Sarcoma

    phase 2 small molecule completed

    1 trial

  13. Gemcitabine Oxaliplatin 5FU and Leucovorin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Pancreatic Cancer

    phase 2 small molecule active

    1 trial

  14. Gemcitabine plus Cisplatin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Biliary Tract Cancer

    phase 2 small molecule active

    1 trial

  15. Gemcitabine+simvastatin

    Samsung Bioepis NL B.V.

    Pancreatic Cancer

    phase 2 small molecule completed

    1 trial

  16. Gemcitabine/Cisplatin

    BRIGHT MINDS BIOSCIENCES INC.

    Upper Tract Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  17. Genomically Directed Monotherapy

    Vera Therapeutics

    Malignant Neoplasm of Breast

    phase 2 small molecule completed

    1 trial

  18. Gentuximab

    The First People's Hospital of Lianyungang

    Advanced Gastric or Gastroesophageal Junction Cancer

    phase 2 small molecule completed

    1 trial

  19. Gentuximab

    Changchun GeneScience Pharmaceutical Co.,

    Advanced Gastric or Gastroesophageal Junction Cancer

    phase 2 small molecule completed

    1 trial

  20. Giapreza 2.5 mg/ml concentrate for solution for infusion

    Disc Medicine

    Liver cancer (primary or secondary)

    phase 2 small molecule active

    1 trial

  21. Gilteritinib

    Astellas Pharma Inc

    Non-Small-Cell Lung Cancer

    phase 2 small molecule terminated

    1 trial

  22. Gimistotug

    BEONE MEDICINES AUS PTY LTD

    Non-Small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  23. Giredestrant

    Hoffmann-La Roche

    Early Breast Cancer

    phase 2 small molecule completed

    1 trial

  24. Giredestrant

    Hoffmann-La Roche

    Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer

    phase 2 small molecule active

    1 trial

  25. Glasdegib

    Jazz Pharmaceuticals Ireland Limited

    Acute Myelogenous Leukemia (AML) Due to Therapy

    phase 2 small molecule active

    1 trial

  26. Gliolan 30 mg/ml powder for oral solution.

    Photonamic GmbH & Co. KG

    Colorectal Carcinoma

    phase 2 small molecule active

    1 trial

  27. Glofitamab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Relapsed or Refractory Aggressive B-cell Lymphoma

    phase 2 small molecule active

    1 trial

  28. Glofitamab for previously untreated aggressive B-cell lymphoma

    The George Institute

    previously untreated aggressive B-cell lymphoma

    phase 2 small molecule active

    1 trial

  29. GnP in combination with Ivonescimab and SBRT

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Pancreatic Cancer

    phase 2 other active

    1 trial

  30. Green tea

    United Therapeutics Europe Ltd

    Lung Cancer Prevention

    phase 2 other completed

    1 trial

  31. Group A (FIT): Avapritinib + IA regimen

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia With T(8;21)(Q22;Q22)

    phase 2 small molecule active

    1 trial

  32. Group A：Patients with PR or ctDNA positivity after salvage treatment

    The First People's Hospital of Lianyungang

    Diffuse Large B-cell Lymphoma(DLBCL)

    phase 2 small molecule active

    1 trial

  33. HAIC + Tislelizumab +lenvatinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Hepatocellular Carcinoma (HCC)

    phase 2 other active

    1 trial

  34. HCD122

    Novartis Pharmaceuticals

    Non-Hodgkin's Lymphoma

    phase 2 small molecule completed

    1 trial

  35. HEC169096

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Advanced Solid Tumor

    phase 2 small molecule active

    1 trial

  36. HEM-iSMART - Sub B

    AXIM BIOTECHNOLOGIES, INC.

    Acute Lymphoblastic Leukemia, in Relapse Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory

    phase 2 small molecule active

    1 trial

  37. HEM-iSMART sub C

    AXIM BIOTECHNOLOGIES, INC.

    Acute Lymphoblastic Leukemia, in Relapse Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory

    phase 2 small molecule active

    1 trial

  38. HER3-DXd

    Daiichi Sankyo

    Advanced Solid Tumor

    phase 2 small molecule active

    1 trial

  39. HKI-272

    PUMA BIOTECHNOLOGY, INC.

    Advanced Breast Cancer

    phase 2 small molecule completed

    2 trials

  40. HKI-272

    PUMA BIOTECHNOLOGY, INC.

    Breast Cancer

    phase 2 small molecule completed

    1 trial

  41. HKI-272

    PUMA BIOTECHNOLOGY, INC.

    Carcinoma, Non-Small-Cell Lung

    phase 2 small molecule completed

    1 trial

  42. HO155

    Wuhan Createrna Science and Technology Co., Ltd

    Acute myeloid leukemia, Myelodysplastic syndrome

    phase 2 small molecule active

    1 trial

  43. HO159

    Wuhan Createrna Science and Technology Co., Ltd

    Patients with relapsed CLL, Chronic lymphocytic leukemia

    phase 2 small molecule active

    1 trial

  44. HO161

    Disc Medicine

    relapsed/refractory Non-Hodgkin Lymphoma

    phase 2 small molecule active

    1 trial

  45. HRS-4642+AG+Nimotuzumab

    Zhejiang University

    Borderline Resectable Pancreatic Adenocarcinoma

    phase 2 small molecule active

    1 trial

  46. HRS-6213

    Jian Li

    Patients With Solid Tumors

    phase 2 small molecule active

    1 trial

  47. HRS-7058

    Shandong Suncadia Medicine Co.,

    Pancreatic Cancer

    phase 2 small molecule active

    1 trial

  48. Herzuma

    Vera Therapeutics

    HER2 Enriched Subtype Breast Cancer, Herzuma, PAM50 Study

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many oncology pipeline programs are tracked?

5,539 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.